Bladder cancer drug developer CG Oncology files IPO
CG Oncology Inc. on Wednesday filed its initial public offering to trade on the Nasdaq under the symbol CGON with underwriters Morgan Stanley, Goldman Sachs & Co LLC, Cantor and LifeSci Capital. The Irvine, Calif.-based company is a late-stage biopharmaceutical company that's developing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Its product candidate, cretostimogene, is initially in clinical development for the treatment of patients with high-risk non-muscle-invasive bladder cancer. Principal shareholders of the company include ORI Capital entities, Decheng Capital Global Life Sciences Fund IV and entities affiliated with Longitude Venture Partners.
-Steve Gelsi
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
01-03-24 0735ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact
-
Tariffs On Chinese EVs Offer US Automakers a Chance to Capture Demand
-
The Best REITs to Buy
-
3 Hot Stocks to Buy That Still Look Undervalued
-
After Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?